Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Meridian Bioscience M. Pneumonia MDx

NEW YORK (GenomeWeb News) – Meridian Bioscience today announced the US Food and Drug Administration cleared its molecular diagnostic test for Mycoplasma pneumonia.

The test is the fourth cleared by FDA to run on the Cincinnati-based company's illumigene platform and follows FDA clearance of Meridian's C. difficile assay, Group B Streptococcus assay, and Group A Streptococcus assay. The M. pneumonia test amplifies specific DNA to detect the bacterium, providing a "definitive result" and ensuring patients receive appropriate treatment in a timely manner, Meridian said.

It added that bacterial culturing for M. pneumonia lacks sensitivity, and because the bacterium may take up to six weeks to culture, the method is "impractical for patient management."

M. pneumonia has been associated with up to 40 percent of community-acquired pneumonia and is most often associated with atypical pneumonia. An estimated 2 million cases of M. pneumonia infections and 100,000 pneumonia-related hospitalizations occur in the US each year, the company said.

Meridian CEO John Kraeutler said that the test will be available for delivery to customers by the end of the month, and told GenomeWeb Daily News in an email that the company expects to file for FDA clearance for its illumigene pertussis test in the fall.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.